USGet the app
Business

CG Oncology: Strong Phase 3 Data Lifts Fair Value, But Leaves Limited Upside

Seekingalpha·
CG Oncology: Strong Phase 3 Data Lifts Fair Value, But Leaves Limited Upside

CG Oncology’s Phase 3 PIVOT-006 trial data lifted an analyst’s risk-adjusted fair value estimate to $82.49, close to the stock’s roughly $83 price. The treatment reduced bladder cancer recurrence risk by 68% compared with surveillance, with no Grade 3 or higher treatment-related adverse events reported. The company plans two biologics license applications in 2027 and says its cash can fund operations through 2029.

Read more at seekingalpha.com
Ad
0Like0Dislike0Comments0Shares

Comments 0

No comments yet. Be the first to share your view in the app.

Join the discussion: comments and votes are in the free Beloud app.